Precision BioSciences to Present PBGENE-HBV at AASLD 2025
October 14, 2025
Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, announced